RxDoctor Payments Data

Gunjan Narwani, MD

Neurology · Kingwood, TXNPI 1699062547

Payments from drug & device makers

$1,245in general payments, 2019–2025

Across 50 payments — averaging $24.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$357
  • AbbVie$206
  • SK Life Science, Inc.$165
  • Medtronic$85
  • Amgen$74
  • Dexcom, Inc.$57
  • plus $300 from 12 others

What the payments were for

  • Food & beverage$1,245100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,245 in reported general payments places this provider in the 40th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$77,108
Medicare patients
360
Services billed
620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate13$13,172
Lacosamide59$4,868
Levetiracetam101$2,855
Memantine Hcl107$2,604
Carbidopa-LevodopaCarbidopa/Levodopa65$1,645
Gabapentin143$1,553
Primidone45$859
Galantamine Hbr11$799
Divalproex Sodium39$777
Carbidopa-Levodopa ErCarbidopa/Levodopa14$733
Donepezil Hcl92$691
RivastigmineRivastigmine Tartrate17$642
Propranolol Hcl36$552
Phenobarbital14$488
Duloxetine Hcl14$472

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$165$13,17213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,246 neurology providers in Texas.

Other neurology in Kingwood

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →